GlaxoSmithKline PLC GSK
-
UPDATE 3-U.S. FDA panel revisits Avandia, likely too late for diabetes drug
… Administration panel of outside experts reopened one of the biggest drug controversies in recent years on Wednesday at a meeting where they will decide whether to recommend lifting marketing restrictions on GlaxoSmithKline Plc 's Avandia diabetes drug.
-
FDA panel revisits Avandia; likely too late for diabetes drug
June 5 (Reuters) - A panel of medical advisers to the U.S. Food and Drug Administration will revive a six-year-old debate over the safety of GlaxoSmithKline Plc 's Avandia diabetes drug, but the...
-
Duke backs safety findings from controversial Avandia trial
June 3 (Reuters) - An independent analysis of a controversial clinical trial appears to back the safety of GlaxoSmithKline Plc 's diabetes drug Avandia, U.S. regulators said on Monday, although scores of smaller trials still raise questions …
-
UPDATE 1-FDA approves two Glaxo melanoma drugs
May 29 (Reuters) - U.S. health regulators on Wednesday approved a pair of GlaxoSmithKline Plc drugs to treat advanced melanoma - the deadliest form of skin cancer - in patients with specific genetic...
-
FDA approves two Glaxo melanoma drugs and companion diagnostic
May 29 (Reuters) - U.S. health regulators on Wednesday approved a pair of GlaxoSmithKline Plc drugs to treat advanced melanoma - the deadliest form of skin cancer - in patients with specific genetic mutations, along with a diagnostic test to detect the mutations.
-
BRIEF-GlaxoSmithKline says positive Arzerra phase 3 results
LONDON, May 29 (Reuters) - GlaxoSmithKline Plc : * Positive top-line phase 3 results from trial of Arzerra (ofatumumab) combined
-
GSK flu shot may raise adult narcolepsy risk -Finnish scientists
HELSINKI/LONDON, May 23 (Reuters) - GlaxoSmithKline Plc 's H1N1 pandemic flu shot may put adults at higher risk of developing narcolepsy, not only children as previous studies found, Finland's National Institute for Health and Welfare said on Thursday.
-
The Billion Dollar COPD Deal: Who Gains The Most?
… PLC ( ELN ) announced a $1 billion deal with Theravance Inc . ( THRX ) for 21% of royalty that it gets from GlaxoSmithKline plc ( GSK ). At the heart of the deal are four COPD (chronic obstructive pulmonary disease) drugs, but the question …
-
New Morningstar Analyst Report - GlaxoSmithKline PLC
Despite growing Advair competition, an improving pipeline sets up Glaxo for steady long-term growth.
-
BRIEF-GSK makes regulatory submission for umeclidinium monotherapy in U.S.
LONDON, April 30 (Reuters) - GlaxoSmithKline Plc : * Regulatory submission for umeclidinium monotherapy in U.S. * Source text for Eikon